Kairos Pharma, Ltd. (NYSE American: KAPA) announced that the U.S. Department of Defense (DoD) is providing $876,000 to support its study of lead compound ENV105 in lung cancer. The grant was awarded to Cedars-Sinai Medical Center to fund research in Dr. Neil Bhowmick’s laboratory.
This funding is specifically for identifying biomarkers in patients with non-small cell carcinoma who have developed resistance to Osimertinib. The goal is to advance a strategy to identify patients starting to develop resistance at an early stage, thereby providing a means to identify those who will benefit from ENV105 treatment.
The DoD grant is a testament to the scientific basis for Kairos Pharma's Phase 1 trial in EGFR-driven lung cancer patients receiving ENV105 in combination with osimertinib. This non-dilutive funding enables the company to progress with its trials while minimizing expenses and managing cash burn.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.